Issues and critiques of the forthcoming Risk Evaluation and Mitigation Strategy (REMS) for opioids in pain management

Issues in Law and Medicine

Volumn 27, Issue 2, 2011, Pages 91-119

  Peppin, John F ^a,b,c,d   Coleman, John J ^e   Kirsh, Kenneth L ^a,d  

^a The Pain Treatment Center of the Bluegrass   (United States)

^b Hospice of the Bluegrass   (United States)

^c Pain Management and Medicine   (United States)

^d Kentucky Prescription Drug Diversion and Abuse Council   (United States)

^e Prescription Drug Research Center   (United States)

Author keywords

Abuse; FDA; Opioids; REMS; Risk management

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ARTICLE; DRUG CONTROL; FOOD AND DRUG ADMINISTRATION; HUMAN; METHODOLOGY; OPIATE ADDICTION; PAIN; RISK ASSESSMENT; RISK MANAGEMENT; UNITED STATES;

ANALGESICS, OPIOID; DRUG AND NARCOTIC CONTROL; HUMANS; OPIOID-RELATED DISORDERS; PAIN; RISK ASSESSMENT; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84859410554     PISSN: 87568160     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. L. Manchikanti, Prescription Drug Abuse: What is Being Done to Address This New Drug Epidemic? Testimony Before the Subcommittee on Criminal Justice, Drug Policy and Human Resources, 9 PAIN PHYSICIAN 287 (2006);
2. National Center on Addiction and Substance Abuse, Controlled Prescription Drug Abuse at Epidemic Level, 20 J. PAIN PALLIAT. CARE PHARMACOTHER. 61 (2006);
3. Office of National Drug Control Policy, Epidemic: Responding to America's Prescription Drug Abuse Crisis 2011, available at http://www. whitehousedrugpolicy.gov/.
4. S.D. Passik, et al., Reality and Responsibility: A Commentary on the Treatment of Pain and Suffering in a Drug-Using Society, 2 J. OPIOID MANAGE. 123 (2006);
5. J.A. Hertz & J.R. Knight, Prescription Drug Misuse: A Growing National Problem, 17 ADOLESC. MED. CLIN. 751 (2006);
6. S.D. Passik, Issues in Long-Term Opioid Therapy: Unmet Needs, Risks, and Solutions, 84 MAYO CLIN. PROC. 593 (2009);
7. and M.J. Wunsch, et al., Oxycontin Use and Misuse in Three Populations: Substance Abuse Patients, Pain Patients, and Criminal Justice Participants, 4 J. OPIOID MANAGE. 73 (2008).
8. In this article the expression "controlled substance" pertains to a pharmaceutical drug that is regulated under the Controlled Substances Act (CSA) of 1970 because of its abuse potential. 4 United Nations, Office of Drugs and Crime, World Drug Report: Drug Markets Stable But Consumption of Synthetic and Prescription Drugs Rises 2011, available at http://www.unodc.org/.
9. D.K. Wysowski, Surveillance of Prescription Drug-Related Mortality Using Death Certificate Data, 30 DRUG SAF. 533 (2007).
10. L.J. Paulozzi, et al., A National Epidemic of Unintentional Prescription Opioid Overdose Deaths: How Physicians Can Help Control It, 72 J. CLIN. PSYCHIATRY 589 (2011).
11. U.S. GENERAL ACCOUNTING OFFICE, PRESCRIPTION DRUGS: OXYCONTIN ABUSE AND DIVERSION AND EFFORTS TO ADDRESS THE PROBLEM (GAO-04-110) (2003), available at http://www.gao.gov/new.items/d04110.pdf (last accessed Jan. 10, 2010);
12. House Government Reform Committee, Subcommittee on Criminal Justice, Drug Policy and Human Resources, Statement of J.T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, on the National Synthetic Drug Control Strategy (2006), available at http://www.dea.gov/pubs/cngrtest/ct061606.html (last accessed Jan. 10, 2010);
13. U.S. Congress, Food and Drug Administration Amendments Act of 2007, P.L. 110-85, 121 Stat. 930 (2007); available at http://thomas.loc.gov/home/thomas. php.
14. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, Stat. 121-823 (Sept. 27, 2007).
15. Food and Drug Administration, Overview of the Family Smoking Prevention and Tobacco Control Act (2011), available at http://www.fda.gov/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/ucm246129.htm.
16. Food and Drug Administration, About the Center for Drug Evaluation and Research (2010), available at http://www.fda.gov/AboutFDA/CentersOffices/CDER/ default.htm.
17. Under the Controlled Substances Act (CSA), when warranted by an evaluation of a drug's abuse potential, the FDA must provide a recommendation for scheduling to the Drug Enforcement Administration (DEA) in order that a drug may be scheduled or placed under the regulatory control of the CSA. Comprehensive Drug Abuse Prevention and Control Act, Title II: Controlled Substances Act, Pub. L. No. 91-513, 84 Stat. 1236, 21 U.S.C. § 811 (1970), available at http://www.gpoaccess.gov/uscode/.
18. OxyContin: Its Use and Abuse, Hearing Before the H. Committee on Energy and Commerce, Serial No. 107-54 (2001), available at http://frwebgate.access. gpo.gov/cgi-bin/getdoc.cgi?dbname=107-house-hearings&docid=f:75754.wais;
19. Hearing to Examine the Effects of the Painkiller OxyContin, Hearing Before the S. Committee on Health, Education, Labor, and Pensions (2002), available at http://prescriptionopioidreform.com/uploads/cong-hearing-Balancing- risk-benefit.pdf;
20. Hearing Before the Subcommittee on Criminal Justice, Drug Policy and Human Resources, Committee on Government Reform (2006) (Food and Drug Administration) (statement of Sandra L. Kweder, M.D., Deputy Director, CDER, FDA), available at http://www.fda.gov/NewsEvents/Testimony/ucm111062.htm.
21. B. Meier, OxyContin Deaths May Top Early Count, N.Y. TIMES, Apr. 15, 2002, available at http://www.nytimes.com/2002/04/15/us/oxycontin-deaths-may- top-earlycount.html?scp=22&sq=OxyContin&st=nyt.
22. P. Tough, The Alchemy of OxyContin, N.Y. TIMES, July 29, 2001, available at http://www.nytimes.com/2001/07/29/magazine/the-alchemy-of-oxycontin.html?ref= oxycontindrug.
23. U.S. GENERAL ACCOUNTING OFFICE, OXYCONTIN ABUSE AND DIVERSION AND EFFORTS TO ADDRESS THE PROBLEM, GAO-04-110 (Dec. 2003), http://www.gao.gov/new.items/ d04110.pdf.
24. FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH, GUIDANCE FOR INDUSTRY: DEVELOPMENT AND USE OF RISK MINIMIZATION ACTION PLANS (2005), available at http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/UCM126830.pdf;
25. FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH, GUIDANCE FOR INDUSTRY: GOOD PHARMACOVIGILANCE PRACTICES AND PHARMACOEPIDEMIOLOGIC ASSESSMENT (2005), available at http://www.fda.gov/ downloads/RegulatoryInformation/Guidances/UCM126834.pdf;
26. The Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System, available at http://www.radars.org/ (last accessed Oct. 26, 2010);
27. Purdue Pharma L.P., Purdue Pharma Implements National Surveillance System to Track Diversion and Abuse of Controlled Pain Medications (2002), available at http://headaches.about.com/blradars.htm.
28. The FDA advised in its RiskMAP materials that it was intending to establish a special Web-based forum for sponsors to obtain and exchange ideas on how to minimize diversion and abuse. "On the same Web site, FDA intends to make available, in summary format, information that has been publicly discussed or otherwise publicly available (from sponsors or other sources) about the effectiveness of particular RiskMAP tools in achieving risk minimization objectives." Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry: Development and Use of Risk Minimization Action Plans (2005), available at http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/UCM126830.pdf. The special Web site, however, was never established.
29. Food and Drug Administration, Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications (2009), available at http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf.
30. Federal Register, Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs, Notice of Public Meeting, Reopening of Comment Period (2009), http://www.regulations.gov/search/Regs/contentStreamer?objectId= 0900006480a44cce &disposition=attachment&contentType=html (last accessed Jan. 16, 2010).
31. Food and Drug Administration, Dec. 4, 2009, FDA/Industry Working Group (IWG) Public Meeting on Risk Evaluation and Mitigation Strategies (REMS) for Certain Opioids (2009), http://www.fda.gov/Drugs/DrugSafety/ InformationbyDrugClass/ucm193499.htm (last accessed Jan. 17, 2010).
32. Industry Working Group (2009), United States Food and Drug Administration, Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs, Public Meeting, Dec. 4, 2009, IWG (PowerPoint Presentation, slide #92), retrieved Mar. 10, 2011, from http://www.fda.gov/downloads/Drugs/DrugSafety/ InformationbyDrugClass/UCM193696.pdf.
33. Food and Drug Administration (2009), Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications," retrieved Mar. 14, 2011, from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM184128.pdf.
34. Food and Drug Administration (2010), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Marriott Inn and Conference Center, University of Maryland University College, 3501 University Boulevard East, Adelphi, MD, July 22 and 23, 2010, Re: Risk Evaluation and Mitigation Strategies (REMS) for Extended Release and Long-Acting Opioid Analgesics, retrieved Mar. 15, 2011, from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM217510.pdf.
35. P.A. Sloan, Opioid Risk Management: Understanding FDA Mandated Risk Evaluation and Mitigation Strategies (REMS), 5 J. OPIOID MANAG. 131-3 (2009).
36. Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, July 22 and 23, 2010, http://www.fda.gov/AdvisoryCommittees/Calendar/ucm214816.htm (last accessed July 6 2010).
37. Personal Observation of Jane A. Axelrad, J.D., at the Joint Meeting of the Food and Drug Administration's Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, University of Maryland, July 22-23, 2010.
38. Food and Drug Administration Amendments Act of 2007, 21 U.S.C. 355-1, Pub. L. No. 110-85, 121 Stat. 926-928 (2007).
39. E.J. Cone, et al., Oxycodone Involvement in Drug Abuse Deaths II: Evidence for Toxic Multiple Drug-Drug Interactions, 28 J. ANALYTICAL TOXICOLOGY 271 (2004a);
40. E.J., Cone, et al., Oxycodone Involvement in Drug Abuse Deaths: Evidence for Toxic Multiple Drug-Drug Interactions, 28 J. ANALYTICAL TOXICOLOGY 616 (2004b).
41. SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, RESULTS FROM THE 2006 NATIONAL SURVEY ON DRUG USE AND HEALTH: NATIONAL FINDINGS, DHHS Pub. No. SMA 07-4293, Rockville, MD (NSDUH Series H-32) (2007).
42. Food and Drug Administration, Approved Risk Evaluation and Mitigation Strategies (REMS)(2011), http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm (last accessed Mar. 10, 2011).
43. Food and Drug Administration, Background on Opioid REMS (2009), available at http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm187975.htm.
44. Pill Card C: Stimulants (photographs of approximately 20 prescription stimulant drugs), in SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, NATIONAL SURVEY ON DRUG USE AND HEALTH (2009), http://www.oas.samhsa.gov/nsduh/ 2k9MRB/2k9pillcards.pdf (last accessed Mar. 14, 2011);
45. U.S. Food and Drug Administration, Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (2011), http://www.accessdata. fda.gov/scripts/cder/ob/docs/tempai.cfm (last accessed Mar. 14, 2011).
46. SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, RESULTS FROM THE 2008 NATIONAL SURVEY ON DRUG USE AND HEALTH: NATIONAL FINDINGS (Office of Applied Studies, NSDUH Series H-36, HHS Pub. No. SMA 09-4434 (2009), App. B (cf. p.142), http://www.oas.samhsa.gov/nsduh/2k8nsduh/AppB.htm (last accessed Mar. 14, 2011).
47. Celgene Corporation, Risk Evaluation and Mitigation Strategies (REMS): System for Thalidomide Education and Prescribing Safety (S.T.E.P.S. ®) (2010), http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM222649.pdf (last accessed Mar. 12, 2011).
48. Purdue Pharma L.P., Risk Evaluation and Mitigation Strategy: OxyContin® (oxycodone hydrochloride controlled-release) Tablets (2010), http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders /UCM220990.pdf (last accessed Mar. 11, 2011).
49. Drug Abuse Treatment Act of 2000, Title XXXV, Sec. 3502 of the Children's Health Act of 2000, http://buprenorphine.samhsa.gov/titlexxxv.html (Substance Abuse and Mental Health Services Administration, CSAT Buprenorphine Information Center website) (last accessed Dec. 20, 2010).
50. See, e.g., C.F. AMERINGER, STATE MEDICAL BOARDS AND THE POLITICS OF PUBLIC PROTECTION (1999).
51. Prescription Drug Abuse Prevention and Treatment Act of 2011, S.B. 507 (introduced by Senator Jay Rockefeller (WV), Mar. 8, 2011), available at http://www.gpo.gov/fdsys/pkg/BILLS-112s507is/pdf/BILLS-112s507is.pdf.